NCT02652936View on ClinicalTrials.gov

A Pharmacokinetics Study of AF-130 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Healthy Volunteers
Interventions
DRUG

AF-130

AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days

DRUG

Placebo comparator

AF-130 matching placebo capsule

Trial Locations (1)

NG11 6JS

Quotient Clinical, Ruddington

All Listed Sponsors
lead

Afferent Pharmaceuticals, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT02652936 - A Pharmacokinetics Study of AF-130 in Healthy Subjects | Biotech Hunter | Biotech Hunter